Banking Partnership Helps Biote Expand Into New Markets
(Visual Description: Truist Securities
Truist title and logo
Terry Weber, CEO, Biote)
Terry Weber: I’m Terry Weber, and I’m the CEO of Biote.
Terry: Biote is really a unique company because we’re totally committed to healthy aging. We want people to feel like they did at their best. You don’t have to age the way your father or your grandfather did. You can be your best self.
(Visual Description: Irving, Texas
Headquarters of Biote)
Terry: The hormone replacement market’s a really interesting market. I think a surprising fact is that 200 million Americans suffer from hormone deficiency. Only 20% get any kind of treatment.
Doctors don’t learn this in med school. So Biote not only trains physicians, but we certify them. To date, we’ve trained about 6,400 medical providers. This is a wonderful start, but we’ve barely scratched the surface.
(Visual Description: Pete Cataldo, Truist Securities – Managing Director, Healthcare Investment Banking)
Pete Cataldo: Biote came to us really at the start of a growth phase, back when the company was contemplating pursuing a merger to become a public company.
Terry: We had real specific needs when we were looking for a banker. I think our first need was we really wanted to significantly expand our sales force. Number two was we were really looking for a path to liquidity. And then the third piece was looking at mergers and acquisitions and other ways to grow.
Pete: There are many different alternatives for them to consider, and so we help them think through those alternatives. And what’s really cool about what Truist is able to provide to a company like Biote is its full suite of services—everything from raising additional growth capital to help pursue their mission. And on the equity front, we were able to provide access to the investment community. We also provided a lot of education around getting additional exposure from a branding perspective in the public markets.
Terry: I loved their depth of the research. I loved the attention to detail. And I really thought that the solutions and options and that critical thinking was there.
(Visual Description: June 3, 2022: Biote rings the closing bell at Nasdaq.)
Terry: Truist really understood who we were and the needs we had growing. So sitting down with the Truist team and working through what each of the paths that we could choose would really put us in the years to come. So that relationship was key for us making very clear decisions at the right point.
Pete: What really started as more of a transaction has turned into a wonderful long-term relationship, and that’s really what we care about at Truist.
(Visual Description: Biote expanded service to all 50 states.
And they’re still growing.)
Terry: We’re just one year public and have completely different needs than we had a year ago. So Truist is there with solutions. They’re nimble, they’re agile. Just truly a partner by all definitions. We’re so excited about the future of Biote. Our providers are asking us for new protocols and new treatments to keep their patients younger and really live healthier and happier rest of their life.
Pete: Biote’s got a great mission, and I’m just really excited about the opportunity ahead of them.
(Visual Description: Imagine tomorrow. Build it today.
Truist Securities
See what this partnership built.)
Disclosure:
©2023 Truist Securities, Inc., member FINRA and SPIC. Truist Securities is a federally registered service mark of Truist Financial Corporation. All rights reserved.